{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:19Z","timestamp":1791908299603,"version":"4.3.4"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["N43\/DBS\/000099."],"award-info":[{"award-number":["N43\/DBS\/000099."]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10072-022-06197-3","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:04:20Z","timestamp":1655431460000},"page":"5479-5500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Comparative safety of high-efficacy disease-modifying therapies in relapsing\u2013remitting multiple sclerosis: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Katarzyna","family":"\u015aladowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0125-0947","authenticated-orcid":false,"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Holko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oktawia","family":"Osiecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"12","key":"6197_CR1","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of multiple sclerosis: a review. Am J Med 133(12):1380-1390.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049","journal-title":"Am J Med"},{"key":"6197_CR2","doi-asserted-by":"publisher","unstructured":"Filippi M, Bar-Or A, Piehl F et al (2018)Multiple sclerosis. Nat Rev Dis Primers 4(43). https:\/\/doi.org\/10.1038\/s41572-018-0041-4","DOI":"10.1038\/s41572-018-0041-4"},{"issue":"suppl 1","key":"6197_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000367614","volume":"72","author":"FD Lublin","year":"2014","unstructured":"Lublin FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(suppl 1):1\u20135. https:\/\/doi.org\/10.1159\/000367614","journal-title":"Eur Neurol"},{"key":"6197_CR4","doi-asserted-by":"publisher","unstructured":"Walton C, King R, Rechtman L et al (2020) Rising prevalance of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J 26(14):1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","DOI":"10.1177\/1352458520970841"},{"key":"6197_CR5","unstructured":"European Medicines Agency https:\/\/www.ema.europa.eu\/en Accessed 1 Dec 2021"},{"key":"6197_CR6","unstructured":"United States Food and Drug Administration https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm Accessed 1 Dec 2021"},{"key":"6197_CR7","unstructured":"Ozanimod (Zeposia\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zeposia-epar-product-information_en.pdf Accessed 1 Dec 2021"},{"key":"6197_CR8","unstructured":"Ofatumumab (Kesimpta\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf Accessed 1 Dec 2021"},{"key":"6197_CR9","unstructured":"Ponesimod (Ponvory\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ponvory-epar-product-information_en.pdf Accessed 1 Dec 2021"},{"issue":"4","key":"6197_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S et al (2015) Association of British Neutrologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol 15(4):273\u2013279. https:\/\/doi.org\/10.1136\/practneurol-2015-001139","journal-title":"Pract Neurol"},{"issue":"4","key":"6197_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/nmt-2020-0016","volume":"10","author":"JS Inshasi","year":"2020","unstructured":"Inshasi JS, Almadani A, Al Fahad S (2020) High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates. Neurodegener Dis Manag 10(4):257\u2013266. https:\/\/doi.org\/10.2217\/nmt-2020-0016","journal-title":"Neurodegener Dis Manag"},{"key":"6197_CR12","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.4103\/1673-5374.239432","volume":"13","author":"F Grand\u2019Maison","year":"2018","unstructured":"Grand\u2019Maison F, Yeung M, Morrow SA et al (2018) Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis, perspectives and approaches. Neural Regen Res 13:1871\u20131874. https:\/\/doi.org\/10.4103\/1673-5374.239432","journal-title":"Neural Regen Res"},{"issue":"6","key":"6197_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo IA, Worthington E, Drudge C et al (2021) Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res 10(6):495\u2013507. https:\/\/doi.org\/10.2217\/cer-2020-0267","journal-title":"J Comp Eff Res"},{"issue":"17","key":"6197_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA et al (2018) Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Neurology 90(17):777\u2013788","journal-title":"Neurology"},{"key":"6197_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 25:215\u2013237. https:\/\/doi.org\/10.1111\/ene.13536","journal-title":"Eur J Neurol"},{"issue":"18","key":"6197_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/cer-2020-0122","volume":"9","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Drudge C et al (2020) Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res 9(18):1255\u20131274. https:\/\/doi.org\/10.2217\/cer-2020-0122","journal-title":"J Comp Eff Res"},{"issue":"6","key":"6197_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102826","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liao Q, Wen H, Zhang Y (2021) Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev 20(6):102826. https:\/\/doi.org\/10.1016\/j.autrev.2021.102826","journal-title":"Autoimmun Rev"},{"issue":"12","key":"6197_CR18","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","volume":"267","author":"H Li","year":"2020","unstructured":"Li H, Hu F, Zhang Y, Li K (2020) Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol 267(12):3489\u20133498. https:\/\/doi.org\/10.1007\/s00415-019-09395-w","journal-title":"J Neurol"},{"issue":"9","key":"6197_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40263-018-0541-5","volume":"32","author":"RC Lucchetta","year":"2018","unstructured":"Lucchetta RC, Tonin FS, Borba HHL et al (2018) Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs 32(9):813\u2013826. https:\/\/doi.org\/10.1007\/s40263-018-0541-5","journal-title":"CNS Drugs"},{"issue":"2","key":"6197_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40120-020-00212-5","volume":"9","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Lang S, Wolff R et al (2020) A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther 9(2):359\u2013374. https:\/\/doi.org\/10.1007\/s40120-020-00212-5","journal-title":"Neurol Ther"},{"key":"6197_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.msard.2019.06.036","volume":"35","author":"RC Lucchetta","year":"2019","unstructured":"Lucchetta RC, Leonart LP, Becker J et al (2019) Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. Mult Scler Relat Disord 35:7\u201315. https:\/\/doi.org\/10.1016\/j.msard.2019.06.036","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"6197_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analysis of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"6197_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"2","key":"6197_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","volume":"17","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC et al (2014) Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR- AMCP-NPC Good Practice Task Force report. Value Health 17(2):157\u2013173. https:\/\/doi.org\/10.1016\/j.jval.2014.01.004","journal-title":"Value Health"},{"issue":"2","key":"6197_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159(2):130\u2013137. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008","journal-title":"Ann Intern Med"},{"key":"6197_CR26","unstructured":"PROSPERO database https:\/\/www.crd.york.ac.uk\/prospero\/ Accessed Dec 2021"},{"key":"6197_CR27","unstructured":"Natalizumab (Tysabri\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tysabri-epar-product-information_en.pdf Accessed 1 Dec 2021"},{"key":"6197_CR28","unstructured":"Fingolimod (Gilanya\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf Accessed 1 Dec 2021"},{"key":"6197_CR29","unstructured":"Cladribine (Mavenclad\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf Accessed 1 Dec 2021"},{"key":"6197_CR30","unstructured":"Alemtuzumab (Lemtrada\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lemtrada-epar-product-information_en-0.pdf Accessed 1 Dec 2021"},{"key":"6197_CR31","unstructured":"Ocrelizumab (Ocrevus\u00ae) SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ocrevus-epar-product-information_en.pdf Accessed 1 Dec 2021"},{"key":"6197_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DS, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"4","key":"6197_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3(4):312\u2013324. https:\/\/doi.org\/10.1002\/jrsm.1058","journal-title":"Res Synth Methods"},{"issue":"12","key":"6197_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115065","volume":"9","author":"B Neupane","year":"2014","unstructured":"Neupane B, Richer D, Bonner AJ et al (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS ONE 9(12):e115065. https:\/\/doi.org\/10.1371\/journal.pone.0115065","journal-title":"PLoS ONE"},{"key":"6197_CR35","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1002\/sim.8383","volume":"38","author":"SC Freeman","year":"2019","unstructured":"Freeman SC, Fisher D, White IR et al (2019) Identifying inconsistency in network meta-analysis: is the net heat plot a reliable method? Stat Med 38:5547\u20135564. https:\/\/doi.org\/10.1002\/sim.8383","journal-title":"Stat Med"},{"key":"6197_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"6197_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/2229-3485.140550","volume":"5","author":"N Bhatnagar","year":"2014","unstructured":"Bhatnagar N, Lakshmi PV, Jeyashree K (2014) Multiple treatment and indirect treatment comparisons: an overview of network metaanalysis. Perspect Clin Res 5(4):154\u2013158. https:\/\/doi.org\/10.4103\/2229-3485.140550","journal-title":"Perspect Clin Res"},{"key":"6197_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/eb-2015-102088","volume":"18","author":"D Mavridis","year":"2015","unstructured":"Mavridis D, Giannatsi M, Cipriani A, Salanti G (2015) A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health 18:40\u201346. https:\/\/doi.org\/10.1136\/eb-2015-102088","journal-title":"Evid Based Ment Health"},{"issue":"9","key":"6197_CR39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"key":"6197_CR40","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00027300 Accessed 1 Dec 2021"},{"issue":"6","key":"6197_CR41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA et al (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383(6):546\u2013557. https:\/\/doi.org\/10.1056\/NEJMoa1917246","journal-title":"N Engl J Med"},{"key":"6197_CR42","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02792218 Accessed 1 Dec 2021"},{"key":"6197_CR43","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005418-31\/BE Accessed 1 Dec 2021"},{"key":"6197_CR44","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02792231 Accessed 1 Dec 2021"},{"key":"6197_CR45","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-005419-33\/DE Accessed 1 Dec 2021"},{"issue":"1","key":"6197_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.2950","volume":"78","author":"BAC Cree","year":"2020","unstructured":"Cree BAC, Goldman MD, Corboy JR et al (2020) Efficacy and safety of 2 fingolimod doses vs glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA Neurol 78(1):1\u201313. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2950","journal-title":"JAMA Neurol"},{"key":"6197_CR47","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01633112 Accessed 1 Dec 2021"},{"key":"6197_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","volume":"8","author":"P O\u2019Connor","year":"2009","unstructured":"O\u2019Connor P, Filippi M, Arnason B et al (2009) 250 \u03bcg or 500 \u03bcg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8:889\u2013897. https:\/\/doi.org\/10.1016\/S1474-4422(09)70226-1","journal-title":"Lancet Neurol"},{"key":"6197_CR49","unstructured":"http:\/\/ClinicalTrials.gov\/show\/NCT00099502 Accessed 1 Dec 2021"},{"issue":"4","key":"6197_CR50","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","volume":"261","author":"TL Vollmer","year":"2014","unstructured":"Vollmer TL, Sorensen PS, Selmaj K et al (2014) A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261(4):773\u2013783. https:\/\/doi.org\/10.1007\/s00415-014-7264-4","journal-title":"J Neurol"},{"key":"6197_CR51","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00605215 Accessed 1 Dec 2021"},{"key":"6197_CR52","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-005450-23\/ES Accessed 1 Dec 2021"},{"key":"6197_CR53","doi-asserted-by":"publisher","unstructured":"CAMMS223 Trial Investigators (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa0802670","DOI":"10.1056\/NEJMoa0802670"},{"key":"6197_CR54","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00050778 Accessed 1 Dec 2021"},{"issue":"9856","key":"6197_CR55","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"key":"6197_CR56","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00530348 Accessed 1 Dec 2021"},{"key":"6197_CR57","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001161-14\/GB Accessed 1 Dec 2021"},{"issue":"9856","key":"6197_CR58","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829\u20131839. https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"6197_CR59","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00548405 Accessed 1 Dec 2021"},{"key":"6197_CR60","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-001162-32\/GB Accessed 1 Dec 2021"},{"issue":"5","key":"6197_CR61","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S et al (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362(5):416\u2013426. https:\/\/doi.org\/10.1056\/NEJMoa0902533","journal-title":"N Engl J Med"},{"issue":"5","key":"6197_CR62","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1352458510391344","volume":"17","author":"S Cook","year":"2011","unstructured":"Cook S, Vermersch P, Comi G et al (2011) Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler 17(5):578\u2013593. https:\/\/doi.org\/10.1177\/1352458510391344","journal-title":"Mult Scler"},{"key":"6197_CR63","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00213135 Accessed 1 Dec 2021"},{"issue":"7","key":"6197_CR64","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/wnl.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45(7):1268\u20131276. https:\/\/doi.org\/10.1212\/wnl.45.7.1268","journal-title":"Neurology"},{"issue":"3","key":"6197_CR65","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ana.23863","volume":"73","author":"FD Lublin","year":"2013","unstructured":"Lublin FD, Cofield SS, Cutter GR et al (2013) Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 73(3):327\u2013340. https:\/\/doi.org\/10.1002\/ana.23863","journal-title":"Ann Neurol"},{"key":"6197_CR66","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.msard.2012.01.006","volume":"1","author":"J Lindsey","year":"2012","unstructured":"Lindsey J, Scott T, Lynch S et al (2012) The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord 1:81\u201386. https:\/\/doi.org\/10.1016\/j.msard.2012.01.006","journal-title":"Mult Scler Relat Disord"},{"key":"6197_CR67","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00211887 Accessed 1 Dec 2021"},{"issue":"12","key":"6197_CR68","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087\u20131097. https:\/\/doi.org\/10.1056\/NEJMoa1206328","journal-title":"N Engl J Med"},{"key":"6197_CR69","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00451451 Accessed 1 Dec 2021"},{"key":"6197_CR70","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-003697-10\/CZ Accessed 1 Dec 2021"},{"issue":"12","key":"6197_CR71","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098\u20131107. https:\/\/doi.org\/10.1056\/NEJMoa1114287","journal-title":"N Engl J Med"},{"key":"6197_CR72","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00420212 Accessed 1 Dec 2021"},{"key":"6197_CR73","doi-asserted-by":"publisher","unstructured":"Panitch H, Goodin DS, Francis G et al (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59(10):1496\u20131506. https:\/\/doi.org\/10.1212\/01.wnl.0000034080.43681.da","DOI":"10.1212\/01.wnl.0000034080.43681.da"},{"key":"6197_CR74","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00292266 Accessed 1 Dec 2021"},{"issue":"5","key":"6197_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"6197_CR76","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00289978 Accessed 1 Dec 2021"},{"issue":"6","key":"6197_CR77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue E-W, Goodin D et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo controlled, phase 3 trial. Lancet Neurol 13(6):545\u2013556. https:\/\/doi.org\/10.1016\/S1474-4422(14)70049-3","journal-title":"Lancet Neurol"},{"key":"6197_CR78","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00355134 Accessed 1 Dec 2021"},{"key":"6197_CR79","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.23938","volume":"73","author":"O Khan","year":"2013","unstructured":"Khan O, Rieckmann P, Boyko A et al (2013) Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 73:705\u2013713. https:\/\/doi.org\/10.1002\/ana.23938","journal-title":"Ann Neurol"},{"key":"6197_CR80","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01067521?term=Gala&cond=Multiple+Sclerosis&draw=2&rank=1 Accessed 1 Dec 2021"},{"key":"6197_CR81","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-018084-27\/results Accessed 1 Dec 2021"},{"key":"6197_CR82","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0140-6736(02)08430-1","volume":"359","author":"L Durelli","year":"2002","unstructured":"Durelli L, Verdun E, Barbero P et al (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet (London, England) 359:1453\u20131460. https:\/\/doi.org\/10.1016\/s0140-6736(02)08430-1","journal-title":"Lancet (London, England)"},{"issue":"7","key":"6197_CR83","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Kieseier BC, Arnold DL et al (2014) Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13(7):657\u2013665. https:\/\/doi.org\/10.1016\/S1474-4422(14)70068-7","journal-title":"Lancet Neurol"},{"key":"6197_CR84","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00906399 Accessed 1 Dec 2021"},{"key":"6197_CR85","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-006333-27\/LV Accessed 1 Dec 2021"},{"key":"6197_CR86","doi-asserted-by":"publisher","unstructured":"IFNB Multiple Sclerosis Study Group (1993) Interferon beta\u20101b is effective in relapsing\u2010remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double\u2010blind, placebo-controlled trial. Neurology 43(4):655\u2013661. https:\/\/doi.org\/10.1212\/wnl.43.4.655","DOI":"10.1212\/wnl.43.4.655"},{"issue":"3","key":"6197_CR87","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39(3):285\u2013294. https:\/\/doi.org\/10.1002\/ana.410390304","journal-title":"Ann Neurol"},{"issue":"3","key":"6197_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234. https:\/\/doi.org\/10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"6197_CR89","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01247324 Accessed 1 Dec 2021"},{"key":"6197_CR90","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01412333 Accessed 1 Dec 2021"},{"key":"6197_CR91","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020315-36\/SK Accessed 1 Dec 2021"},{"key":"6197_CR92","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020337-99\/GB Accessed 1 Dec 2021"},{"issue":"5","key":"6197_CR93","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M et al (2021) Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 78(5):558\u2013567. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0405","journal-title":"JAMA Neurol"},{"key":"6197_CR94","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02425644 Accessed 1 Dec 2021"},{"key":"6197_CR95","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-000540-10\/DE Accessed 1 Dec 2021"},{"issue":"9139","key":"6197_CR96","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"GC Ebers","year":"1998","unstructured":"Ebers GC, PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 352(9139):1498\u20131504. https:\/\/doi.org\/10.1016\/S0140-6736(98)03334-0","journal-title":"Lancet"},{"issue":"11","key":"6197_CR97","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","volume":"18","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW et al (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, Phase III trial. Lancet Neurol 18(11):1021\u20131033. https:\/\/doi.org\/10.1016\/S1474-4422(19)30238-8","journal-title":"Lancet Neurol"},{"key":"6197_CR98","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-002714-40\/IT Accessed 1 Dec 2021"},{"key":"6197_CR99","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02047734 Accessed 1 Dec 2021"},{"issue":"10","key":"6197_CR100","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, Barkhof F, Chang P et al (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7(10):903\u2013914. https:\/\/doi.org\/10.1016\/S1474-4422(08)70200-X","journal-title":"Lancet Neurol"},{"key":"6197_CR101","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00078338 Accessed 1 Dec 2021"},{"issue":"11","key":"6197_CR102","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW et al (2019) Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, Phase III trial. Lancet Neurol 18(11):1009\u20131020. https:\/\/doi.org\/10.1016\/S1474-4422(19)30239-X","journal-title":"Lancet Neurol"},{"key":"6197_CR103","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-002320-27\/EE Accessed 1 Dec 2021"},{"key":"6197_CR104","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02294058 Accessed 1 Dec 2021"},{"issue":"14","key":"6197_CR105","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O\u2019Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293\u20131303. https:\/\/doi.org\/10.1056\/NEJMoa1014656","journal-title":"N Engl J Med"},{"key":"6197_CR106","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00134563 Accessed 1 Dec 2021"},{"key":"6197_CR107","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-000555-42\/NO Accessed 1 Dec 2021"},{"issue":"6","key":"6197_CR108","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LM et al (2014) Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 20(6):705\u2013716. https:\/\/doi.org\/10.1177\/1352458513507821","journal-title":"Mult Scler"},{"key":"6197_CR109","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00883337 Accessed 1 Dec 2021"},{"key":"6197_CR110","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-006226-34\/ES Accessed 1 Dec 2021"},{"issue":"3","key":"6197_CR111","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247\u2013256. https:\/\/doi.org\/10.1016\/S1474-4422(13)70308-9","journal-title":"Lancet Neurol"},{"key":"6197_CR112","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00751881 Accessed 1 Dec 2021"},{"key":"6197_CR113","unstructured":"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-004452-36\/GB Accessed 1 Dec 2021"},{"issue":"5","key":"6197_CR114","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402\u2013415. https:\/\/doi.org\/10.1056\/NEJMoa0907839","journal-title":"N Engl J Med"},{"key":"6197_CR115","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00340834 Accessed 1 Dec 2021"},{"issue":"5","key":"6197_CR116","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7224\/1537-2073.2014-035","volume":"17","author":"RE Nelson","year":"2015","unstructured":"Nelson RE, Xie Y, DuVall S et al (2015) Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care 17(5):221\u2013230. https:\/\/doi.org\/10.7224\/1537-2073.2014-035","journal-title":"Int J MS Care"},{"key":"6197_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102420","volume":"45","author":"A Castelo-Branco","year":"2020","unstructured":"Castelo-Branco A, Chiesa F, Conte S et al (2020) Infections in patients with multiple sclerosis: a national cohort study in Sweden. Mult Scler Relat Disord 45:102420. https:\/\/doi.org\/10.1016\/j.msard.2020.102420","journal-title":"Mult Scler Relat Disord"},{"key":"6197_CR118","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2147\/TCRM.S134398","volume":"13","author":"C Guarnera","year":"2017","unstructured":"Guarnera C, Bramanti P, Mazzon E (2017) Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag 13:871\u2013879. https:\/\/doi.org\/10.2147\/TCRM.S134398","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"6197_CR119","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/jamaneurol.2019.2670","volume":"77","author":"S Vukusic","year":"2020","unstructured":"Vukusic S, Rollot F, Casey R (2020) Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France. JAMA Neurol 77(1):94\u2013102. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2670","journal-title":"JAMA Neurol"},{"key":"6197_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286419836571","volume":"12","author":"L Klotz","year":"2019","unstructured":"Klotz L, Havla J, Schwab et al (2019) Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 12:1\u201331","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06197-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:12:51Z","timestamp":1660695171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06197-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":120,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6197"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06197-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}